Imatinib (Gleevec), a small molecule inhibitor against BCR-ABL, KIT, and PDGFR, shows the inhibitory effect on GISTs and has been approved for KIT-positive GIST as the first-line treatment. This evidence concerns the gene ABL1 and gastrointestinal stromal tumor.